GRAL → $150.00 by May 18, 2025.

In recent weeks, Grail (GRAL) has seen a significant increase in interest, driven by the broader excitement around AI applications in healthcare. While much of the AI hype has focused on drug discovery for cancer treatment, Grail stands out for its use of AI to detect cancer in its earliest stages—before symptoms appear—through its Galleri test. # Why Is Grail Gaining Attention? The Galleri test is a multi-cancer early detection (MCED) test capable of identifying over 50 types of cancer …